Quest Diagnostics published a study revealing that a significant portion of Lyme disease patients also carry other tick-borne pathogens, highlighting the need for comprehensive testing. This research underscores Quest's expertise in infectious disease diagnostics and could drive demand for their broader testing panels.
Quest Diagnostics (DGX) released a study indicating that nearly 30% of patients with Lyme disease antibodies also have antibodies for other tick-borne pathogens. This finding is significant because it highlights the complexity of tick-borne illnesses and the potential for misdiagnosis if only single-pathogen testing is used, especially since co-infections like Babesiosis require different treatments than Lyme disease. For Quest Diagnostics, this research reinforces their position as a leader in infectious disease diagnostics and could lead to increased demand for their comprehensive tick-borne disease testing panels, offering a long-term opportunity for revenue growth. The study's emphasis on the need for comprehensive testing could also influence healthcare providers to adopt broader diagnostic approaches, benefiting companies like Quest that offer such services.